Viatris Inc. (VTRS) has a MoatMap StockRank of 95/100 based on Quality (41/100), Value (62/100), and Momentum (80/100) factor scores. The current signal is STRONG BUY. Viatris is a generic pharmaceutical manufacturer. Under our CDMO theme, generic drug makers are classified as casualties due to thin margins, high input costs, and lack of pricing power compared to high-moat biologics CDMOs.
Viatris Inc. is a global healthcare company formed through the combination of Mylan and Upjohn, specializing in the development, manufacture, and sale of branded, generic, and biosimilar medicines. Its competitive moat is derived from a highly diversified product portfolio, global manufacturing and supply chain capabilities, and broad geographic reach across over 165 countries. Viatris operates as a major global pharmaceutical player, providing access to essential medicines and addressing unmet patient needs worldwide.
| Price | $15.90 |
| Market Cap | $18.8B |
| P/E (Forward) | 5.94 |
| Price/Book | 1.24 |
| Return on Equity | -2.0% |
| Return on Invested Capital | -10.6% |
| Debt/Equity | 99.67 |
| Gross Margin | 39.8% |
| Operating Margin | 6.8% |
| Revenue Growth | 8.1% |
| Dividend Yield | 3.0% |
| Free Cash Flow | $2.2B |
Viatris Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).